Peptide News Digest

#Access

2 stories

Clinical Trials · View digest

Structure Therapeutics Aleniglipron Hits Day 1 of ADA With Simultaneous Nature Medicine Publication and Full Phase 2b ACCESS Oral Presentation

Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.

Industry · View digest

Amazon One Medical Launches National GLP-1 Weight Loss Program at $25/Month

Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.